For research use only. Not for therapeutic Use.
Montelukast-d6 Sodium (CAS: 2673270-26-1), a high-quality pharmaceutical research compound designed for advanced studies in asthma and allergy treatment research. As a deuterated analog of Montelukast sodium, it offers enhanced stability and improved pharmacokinetic properties. Montelukast-d6 Sodium is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel therapies for asthma and allergic conditions. Trusted by leading laboratories, Montelukast-d6 Sodium is your go-to solution for cutting-edge respiratory and allergy research. Unlock new possibilities in asthma and allergy treatment with Montelukast-d6 Sodium, where innovation meets reliability.
| Catalog Number | S000128 |
| CAS Number | 2673270-26-1 |
| Molecular Formula | C35H29D6ClNNaO3S |
| Purity | ≥95% |
| Target | Leukotriene Receptor |
| IUPAC Name | sodium;2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(1,1,1,3,3,3-hexadeuterio-2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetate |
| InChI | InChI=1S/C35H36ClNO3S.Na/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29;/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39);/q;+1/p-1/b15-10+;/t32-;/m1./s1/i1D3,2D3; |
| InChIKey | LBFBRXGCXUHRJY-KSWPWUDBSA-M |
| SMILES | [2H]C([2H])([2H])C(C1=CC=CC=C1CC[C@H](C2=CC=CC(=C2)/C=C/C3=NC4=C(C=CC(=C4)Cl)C=C3)SCC5(CC5)CC(=O)[O-])(C([2H])([2H])[2H])O.[Na+] |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Pu S, et, al. Montelukast Prevents Mice Against Acetaminophen-Induced Liver Injury. Front Pharmacol. 2019 Sep 18; 10:1070.;William RHJ, et, al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med. 2002 Jan 1; 165(1): 108-16. |
